Literature DB >> 1554844

Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.

P M Strebel1, R W Sutter, S L Cochi, R J Biellik, E W Brink, O M Kew, M A Pallansch, W A Orenstein, A R Hinman.   

Abstract

Poliomyelitis caused by wild poliovirus has been virtually nonexistent in the United States since 1980, and vaccine-associated paralytic poliomyelitis (VAPP) has emerged as the predominant form of the disease. We reviewed national surveillance data on poliomyelitis for 1960-1989 to assess the changing risks of wild-virus, vaccine-associated, and imported paralytic disease; we also sought to characterize the epidemiology of poliomyelitis for the period 1980-1989. The risk of VAPP has remained exceedingly low but stable since the mid-1960s, with approximately 1 case occurring per 2.5 million doses of oral poliovirus vaccine (OPV) distributed during 1980-1989. Since 1980 no indigenous cases of wild-virus disease, 80 cases of VAPP, and five cases of imported disease have been reported in the United States. Three distinct groups are at risk of vaccine-associated disease: recipients of OPV (usually infants receiving their first dose), persons in contact with OPV recipients (mostly unvaccinated or inadequately vaccinated adults), and immunologically abnormal individuals. Overall, 93% of cases in OPV recipients and 76% of vaccine-associated cases have been related to administration of the first or second dose of OPV. Our findings suggest that adoption of a sequential vaccination schedule (inactivated poliovirus vaccine followed by OPV) would be effective in decreasing the risk of VAPP while retaining the proven public health benefits of OPV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554844     DOI: 10.1093/clinids/14.2.568

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  68 in total

1.  Serum antibodies to polioviruses in Alexandria, Egypt.

Authors:  R Gabrieli; M Divizia; E El Ghazzawi; O A Kader; Z El Gawhary; E Renganathan; A Panà
Journal:  Eur J Epidemiol       Date:  1999-03       Impact factor: 8.082

2.  Polio eradication--target 2000.

Authors:  S Gomber; K N Agarwal
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

3.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Retrospective study on poliomyelitis cases in northern Greece.

Authors:  Filanthi Frantzidou; Anna Papa; Dimitra Chalkia; Antonis Antoniadis
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

5.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

6.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Evaluating the safety of new vaccines: summary of a workshop.

Authors:  Susan S Ellenberg; Mary A Foulkes; Karen Midthun; Karen L Goldenthal
Journal:  Am J Public Health       Date:  2005-05       Impact factor: 9.308

Review 8.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

9.  Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91.

Authors:  J K Andrus; P M Strebel; C A de Quadros; J M Olivé
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

Review 10.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.